teensexonline.com

Why Eiger BioPharma (EIGR) Shares Are Gaining Today – Eiger BioPharmaceuticals (NASDAQ:EIGR)

Date:

  • Eiger BioPharmaceuticals Inc EIGR announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. 
  • The data exhibited that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger’s investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. 
  • The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours. 
  • Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in the hospital and on a ventilator, and adverse events. 
  • In the study, 931 patients received peginterferon lambda, and 1,018 received a placebo. 
  • The publication detailed results, highlighting a 51% reduction in the risk of hospitalization or emergency room visits (primary endpoint) with peginterferon lambda.
  • Lambda reduced the risk of hospitalization by 42% and COVID-19-related death by 50%
  • RelatedEiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment.
  • The risk of COVID-19 hospitalization or all-cause death was reduced by 47% in participants receiving peginterferon lambda. 
  • In patients receiving treatment within three days of symptom onset, greater treatment effects were observed in the peginterferon lambda group, including a 65% reduction of COVID-19-related hospitalization, 81% risk reduction in all-cause death, and 89% risk reduction among unvaccinated patients.
  • Price Action: EIGR shares are up 39.9% at $2.85 on the last check Thursday.

Share post:

Subscribe

Popular

More like this
Related